Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Journal of Clinical Pharmacy and Therapeutics Pub Date : 2022-12-13 DOI:10.1111/jcpt.13800

Katrina Ciraldo MD, Manuel Seraydarian Pharm D, James Gasper Pharm D, BCPP, Triveni DeFries MD, MPH, Marlene Martin MD

{"title":"Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series","authors":"Katrina Ciraldo MD, Manuel Seraydarian Pharm D, James Gasper Pharm D, BCPP, Triveni DeFries MD, MPH, Marlene Martin MD","doi":"10.1111/jcpt.13800","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> What is known and objective</h3>\n \n <p>Individuals with medication adherence challenges or a preference for long-acting medications may benefit from extended-release naltrexone (XR-NTX) for treatment of alcohol use disorder (AUD). Individuals on therapeutic anticoagulation were excluded from XR-NTX studies and its safety in this population has not been reported.</p>\n </section>\n \n <section>\n \n <h3> Case summary</h3>\n \n <p>We conducted structured retrospective chart review of six individuals who received XR-NTX for AUD while on therapeutic anticoagulation between November 2019 and Deccember 2020. We found no documented complications among six individuals who received up to 11 doses of XR-NTX while on therapeutic anticoagulation.</p>\n </section>\n \n <section>\n \n <h3> What is new and conclusion</h3>\n \n <p>XR-NTX may be safely tolerated by patients on therapeutic anticoagulation. We need larger studies evaluating XR-NTX administration in patients on therapeutic anticoagulation and those with coagulopathies, including individuals with alcohol-related liver disease, to better quantify risks and benefits for shared decision-making.</p>\n </section>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13800","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

What is known and objective

Individuals with medication adherence challenges or a preference for long-acting medications may benefit from extended-release naltrexone (XR-NTX) for treatment of alcohol use disorder (AUD). Individuals on therapeutic anticoagulation were excluded from XR-NTX studies and its safety in this population has not been reported.

Case summary

We conducted structured retrospective chart review of six individuals who received XR-NTX for AUD while on therapeutic anticoagulation between November 2019 and Deccember 2020. We found no documented complications among six individuals who received up to 11 doses of XR-NTX while on therapeutic anticoagulation.

What is new and conclusion

XR-NTX may be safely tolerated by patients on therapeutic anticoagulation. We need larger studies evaluating XR-NTX administration in patients on therapeutic anticoagulation and those with coagulopathies, including individuals with alcohol-related liver disease, to better quantify risks and benefits for shared decision-making.

Abstract Image

查看原文本刊更多论文

缓释纳曲酮对酒精使用障碍患者的抗凝治疗:一个病例系列

有药物依从性挑战或偏好长效药物的个体可能受益于缓释纳曲酮(XR-NTX)治疗酒精使用障碍(AUD)。接受治疗性抗凝治疗的个体被排除在XR-NTX研究之外，其在该人群中的安全性尚未报道。我们对2019年11月至2020年12月期间接受治疗性抗凝治疗的6例AUD患者进行了结构化回顾性图表回顾。我们发现6名在治疗性抗凝治疗中接受11剂量XR-NTX治疗的患者没有出现并发症。XR-NTX可安全耐受治疗抗凝患者。我们需要更大规模的研究来评估XR-NTX在治疗性抗凝治疗患者和凝血功能障碍患者(包括酒精相关性肝病患者)中的应用，以便更好地量化共同决策的风险和收益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Pharmacy and Therapeutics 医学-药学

CiteScore

4.10

自引率

5.00%

发文量

226

审稿时长

6 months

期刊介绍： The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.